Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia

Z. Král, J. Michalka, H. Móciková, J. Marková, A. Sýkorová, D. Belada, A. Jungová, S. Vokurka, M. Lukášová, V. Procházka, J. Ďuraš, R. Hájek, L. Dušek, Ľ. Drgoňa, M. Ladická, V. Ballová, A. Vranovský,

. 2019 ; 10 (21) : 5041-5048. [pub] 20190828

Language English Country Australia

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc19044223

Introduction: Clinical trials have demonstrated the effectiveness of the CD30-targeted antibody-drug conjugate brentuximab vedotin (BV) for the treatment of relapsed/refractory Hodgkin lymphoma (R/R HL). In this study, we report on outcomes with BV in a real-world setting using data collected in clinics in the Czech Republic and Slovakia. Patients and Methods: Clinical and epidemiological data for patients with R/R HL who received treatment with BV at eight centers across the Czech Republic and Slovakia were examined. Data were amalgamated and analyzed retrospectively. Results: Clinical data for 58 patients (median age: 30.5 years) with R/R HL who received BV during the course of their treatment were collected and analyzed. Patients had received a median of 3 prior treatment regimens and most (91%) were treated with BV after relapse following autologous stem cell transplantation. Therapeutic responses after BV included 19 (33%) complete responses (CRs) and 8 (14%) partial responses. CRs occurred more frequently in patients who had received fewer prior treatment regimens. The 1-, 2-, and 3-year overall survival (OS) rates from initiation of BV were 78%, 62%, and 41%, respectively. Conclusion: Response rates and OS in this analysis of BV in real-world settings in the Czech Republic and Slovakia were consistent with those reported for pivotal clinical trials and from previous studies outside the clinical trial setting. The results support the efficacy of BV for treatment of R/R HL in real-life clinical practice.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19044223
003      
CZ-PrNML
005      
20200109095612.0
007      
ta
008      
200107s2019 at f 000 0|eng||
009      
AR
024    7_
$a 10.7150/jca.29308 $2 doi
035    __
$a (PubMed)31602255
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a at
100    1_
$a Král, Zdeněk $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
245    10
$a Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia / $c Z. Král, J. Michalka, H. Móciková, J. Marková, A. Sýkorová, D. Belada, A. Jungová, S. Vokurka, M. Lukášová, V. Procházka, J. Ďuraš, R. Hájek, L. Dušek, Ľ. Drgoňa, M. Ladická, V. Ballová, A. Vranovský,
520    9_
$a Introduction: Clinical trials have demonstrated the effectiveness of the CD30-targeted antibody-drug conjugate brentuximab vedotin (BV) for the treatment of relapsed/refractory Hodgkin lymphoma (R/R HL). In this study, we report on outcomes with BV in a real-world setting using data collected in clinics in the Czech Republic and Slovakia. Patients and Methods: Clinical and epidemiological data for patients with R/R HL who received treatment with BV at eight centers across the Czech Republic and Slovakia were examined. Data were amalgamated and analyzed retrospectively. Results: Clinical data for 58 patients (median age: 30.5 years) with R/R HL who received BV during the course of their treatment were collected and analyzed. Patients had received a median of 3 prior treatment regimens and most (91%) were treated with BV after relapse following autologous stem cell transplantation. Therapeutic responses after BV included 19 (33%) complete responses (CRs) and 8 (14%) partial responses. CRs occurred more frequently in patients who had received fewer prior treatment regimens. The 1-, 2-, and 3-year overall survival (OS) rates from initiation of BV were 78%, 62%, and 41%, respectively. Conclusion: Response rates and OS in this analysis of BV in real-world settings in the Czech Republic and Slovakia were consistent with those reported for pivotal clinical trials and from previous studies outside the clinical trial setting. The results support the efficacy of BV for treatment of R/R HL in real-life clinical practice.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Michalka, Jozef $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Móciková, Heidi $u Department of Clinical Hematology, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Marková, Jana $u Department of Clinical Hematology, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Sýkorová, Alice $u 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove, Czech Republic and Charles University in Prague, Faculty of Medicine in Hradec Kralove, Czech Republic.
700    1_
$a Belada, David $u 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove, Czech Republic and Charles University in Prague, Faculty of Medicine in Hradec Kralove, Czech Republic.
700    1_
$a Jungová, Alexandra $u Department of Haemato-Oncology, University Hospital in Plzen, Plzen 304 60, Czech Republic.
700    1_
$a Vokurka, Samuel $u Department of Haemato-Oncology, University Hospital in Plzen, Plzen 304 60, Czech Republic.
700    1_
$a Lukášová, Marie $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic.
700    1_
$a Procházka, Vít $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic.
700    1_
$a Ďuraš, Juraj $u Department of Hemato-Oncology, Faculty of Medicine, University of Ostrava and University Hospital Ostrava, Ostrava, Czech Republic.
700    1_
$a Hájek, Roman $u Department of Hemato-Oncology, Faculty of Medicine, University of Ostrava and University Hospital Ostrava, Ostrava, Czech Republic.
700    1_
$a Dušek, Ladislav $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Czech Republic.
700    1_
$a Drgoňa, Ľuboš $u Department of Oncohematology, Comenius University in Bratislava and National Cancer Institute, Bratislava, Slovakia.
700    1_
$a Ladická, Miriam $u Department of Oncohematology, Comenius University in Bratislava and National Cancer Institute, Bratislava, Slovakia.
700    1_
$a Ballová, Veronika $u Department of Hematology/Oncology, Kantonsspital Baden, Baden, Switzerland.
700    1_
$a Vranovský, Andrej $u Department of Oncohematology, Comenius University in Bratislava and National Cancer Institute, Bratislava, Slovakia.
773    0_
$w MED00188770 $t Journal of Cancer $x 1837-9664 $g Roč. 10, č. 21 (2019), s. 5041-5048
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31602255 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200107 $b ABA008
991    __
$a 20200109095941 $b ABA008
999    __
$a ind $b bmc $g 1480812 $s 1082893
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 10 $c 21 $d 5041-5048 $e 20190828 $i 1837-9664 $m Journal of Cancer $n J Cancer $x MED00188770
LZP    __
$a Pubmed-20200107

Find record

Citation metrics

Archiving options